Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.
miRecule, a biotechnology company developing RNA therapies, and GBI Biomanufacturing, a CDMO, entered a strategic partnership to advance the development and clinical supply of miRecule’s Antibody-RNA ...
Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback